In the calculus of modern farming, what's left behind after harvest is often a cost. Corn stalks, wheat straw, and other crop residues must be managed, sometimes tilled under at a fuel expense or left to decompose slowly. For a Chicago biotech startup, that residue represents a locked-up bank of nutrients, and the key is a precise mix of fungi, bacteria, and yeast.
IMIO, founded in 2018, develops what it calls dependable biologicals for commercial growers. Its central bet is that by introducing a specific microbial consortium directly onto crop residue, farmers can accelerate natural decomposition, unlock nitrogen, phosphorus, and potassium for the next planting, and reduce their reliance on synthetic fertilizer. The company's recent $12 million seed round, led by European life sciences investor Sofinnova Partners, suggests institutional capital is beginning to take that bet seriously [Businesswire, October 2026].
A biological wedge into the fertilizer budget
IMIO's flagship product, Re-Gen, is a freeze-dried powder that growers mix with water and spray onto leftover biomass after harvest. The company positions it not as another soil amendment, but as a tool for nutrient recapture. The premise is direct inoculation: instead of relying on the slow, variable process of composting or natural soil microbes to break down tough lignin and cellulose, Re-Gen places what it claims are 100,000 times more active microbes directly onto the residue [IMIO, retrieved 2026].
This approach, the company says, works in weeks rather than the year or more required for traditional composting, and converts the residue into bioavailable nutrients for the subsequent crop [IMIO, retrieved 2026]. For a farmer, the value proposition is framed in dollars per acre. IMIO claims Re-Gen can unlock up to $293 per acre in NPK fertilizer value for row crops, effectively creating a credit against their chemical fertilizer purchases [jefffernandez.com/career]. Early trial data cited by the company points to an average yield increase of 11.9 bushels per acre in corn [IMIO, retrieved 2024].
The team and a strategic partner
The company is led by co-founders Charles Smith, CEO, and Victoria Holden, the Chief Scientific Officer. Holden holds a Ph.D. in microbiology and immunology, bringing academic heft to the startup's biological claims [kisorganics.com, retrieved 2026]. Their advisory bench includes Jeff Fernandez, a founding advisor who helped establish the company's initial product-market fit and institutional foundations [jefffernandez.com/career].
A significant vote of confidence came in July 2026, not from a traditional VC, but from Chipotle's Cultivate Next venture fund. The strategic investment ties IMIO's mission of nutrient efficiency directly to the restaurant chain's broader goals for a more resilient food supply chain [Chipotle Newsroom, July 2026]. This was followed months later by the larger Sofinnova-led round, which included participation from Starshot Capital and Grow Together Salinas, relocating the company to Chicago's Bucktown neighborhood [Crain’s Chicago Business, October 2026].
| Round | Amount | Lead Investor | Key Participants | Date |
|---|---|---|---|---|
| Seed | $12,000,000 | Sofinnova Partners | Chipotle's Cultivate Next, Starshot Capital, Grow Together Salinas, Earth Foundry, Serra Ventures | October 2026 |
| Strategic Investment | Undisclosed | Chipotle's Cultivate Next | Not disclosed | July 2026 |
| Grant/Other | $2,770,000 (estimated) | Unknown (possibly NSF) | Not applicable | Date unknown [CB Insights, retrieved 2026] |
A second product and the path to market
While Re-Gen targets broad-acre field crops, IMIO has a second product, Root, designed for a different problem. Root is a microbial inoculant aimed at producing plant-growth hormones to strengthen root systems and reduce transplant shock. It is marketed as a natural alternative to synthetic rooting gels, particularly in controlled-environment agriculture like cannabis propagation [IMIO, retrieved 2024]. One case study cited by the company involved a cannabis grower using Root to address a fungal pathogen, reportedly achieving a very high cloning success rate [Modernizing Medicine Daily, October 2026].
This two-product approach gives IMIO a wedge into both large-scale nutrient management and higher-value specialty cultivation. The company's reported user base includes commercial row-crop and produce growers, suggesting it is moving beyond early trials into commercial deployment [jefffernandez.com/career].
The counterfactuals in a crowded field
The agricultural biologicals sector is bustling with startups promising to replace or reduce synthetic inputs. IMIO's differentiation rests on its specific mechanism,direct residue inoculation,and its quantified claims of speed and nutrient credit value. However, the path for any new biological is fraught with biological and commercial variables.
- Field variability. Soil health, climate, and residue type can all influence microbial efficacy. A product that delivers consistent results across diverse geographies and farming practices is the holy grail, but difficult to prove at scale without years of third-party, replicated trials.
- Grower adoption. Changing a farmer's practice, especially one tied to core inputs like fertilizer, requires overwhelming proof of economic return and operational simplicity. The cost-benefit must be crystal clear and resilient to bad growing seasons.
- Competitive landscape. While no direct competitors are named in IMIO's sources, the company is competing against a host of other microbial products, advanced compost technologies, and the entrenched habit of simply applying more synthetic fertilizer.
IMIO's answer to these risks appears to be a focus on dependability and clear economic math, backed by a scientific co-founder and strategic investors aligned with long-term supply chain health. The partnership with Chipotle provides a potential route to offtake and validated demand from a major buyer.
For the commercial corn or soybean grower managing thousands of acres, the standard of care today is a complex dance of soil testing, synthetic fertilizer application, and residue management, often involving tillage. Fertilizer represents one of the largest variable costs, subject to volatile global markets. A product that reliably converts waste biomass into a predictable nutrient credit could shift that economic equation, turning a cost center into a modest asset. That is the patient population IMIO is trying to serve: row-crop farmers squeezed between input costs and commodity prices, for whom a few extra bushels and a few dozen dollars saved per acre can define a season's profitability.
The next twelve months will be about scaling proof. The infusion of $12 million provides runway to expand field trials, build out manufacturing for its freeze-dried products, and deepen relationships with large growers. The real milestone to watch will be the publication of broader, independent data that either corroborates or tempers the per-acre value claims. In biotech, even for the soil, peer review is the ultimate gatekeeper.
Sources
- [Businesswire, October 2026] IMIO raises $12 million | https://www.businesswire.com/newsroom?industry=1000025
- [IMIO, retrieved 2026] Product claims and mechanisms | https://www.imio.co/
- [jefffernandez.com/career] Advisor perspective and value claims | https://www.jefffernandez.com/career
- [Chipotle Newsroom, July 2026] Cultivate Next Fund investment | https://newsroom.chipotle.com/2026-07-08-CHIPOTLES-CULTIVATE-NEXT-FUND-INVESTS-IN-SIX-EMERGING-COMPANIES-BUILDING-A-MORE-RESILIENT-FOOD-SYSTEM
- [Crain’s Chicago Business, October 2026] Ag biotech startup Imio lands $12M, relocates to Chicago | https://www.bizjournals.com/chicago/news/2026/10/20/argicultural-biotech-startup-imio-bucktown-12m.html
- [Modernizing Medicine Daily, October 2026] Case study on Root product | https://www.mmjdaily.com/article/9550134/many-growers-were-looking-for-an-organic-alternative-in-their-cloning-process/
- [kisorganics.com, retrieved 2026] Team background | https://kisorganics.com
- [CB Insights, retrieved 2026] Earlier funding data | https://www.cbinsights.com